摘要
BACKGROUND Although oxaliplatin is widely established as a standard treatment in colorectal cancer(CRC),oxaliplatin-induced neuropathy has emerged as a prominent doselimiting side effect associated with quality of life decrements.Ongoing monitoring and management of neuropathy is important for CRC patient quality of life and adherence to treatment.Therefore,a validated self-reported measure of neuropathy would aid in the management and assessment of oxaliplatininduced neuropathy in clinical practice and research.We sought to evaluate the content validity of the 13-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale(FACT/GOGNtx)for CRC patients receiving oxaliplatin.AIM To understand the neuropathy experiences of CRC patients and assess content validity of the FACT/GOG-Ntx.METHODS Semi-structured concept elicitation and cognitive debriefing interviews were conducted with 31 CRC patients experiencing peripheral neuropathy from current or previous oxaliplatin treatment.Interview data were analyzed using a constant comparative approach,and data were mapped to the FACT/GOG-Ntx to assess content validity.RESULTS Mean age of the sample was 54(range 34-82).The sample was primarily Caucasian(84%)and consisted of nearly equal numbers of men and women.Participants described 28 unique neuropathy symptoms;hand tingling(experienced by 87%of respondents);feet tingling(81%);hand numbness(68%);and feet numbness(84%)were most frequently mentioned.Neuropathy symptoms occurring on the feet were most often identified as most bothersome by participants.Eleven of the 13 FACT/GOG-Ntx items exhibited moderate to strong evidence of content validity.Two items related to trouble hearing and ringing in the ears had weak support;however,these items represent severe neuropathy and could be useful for a patient reported outcome measure.CONCLUSION The FACT/GOG-Ntx represents the key neuropathy experiences of CRC patients treated with oxaliplatin.
BACKGROUND Although oxaliplatin is widely established as a standard treatment in colorectal cancer(CRC), oxaliplatin-induced neuropathy has emerged as a prominent doselimiting side effect associated with quality of life decrements. Ongoing monitoring and management of neuropathy is important for CRC patient quality of life and adherence to treatment. Therefore, a validated self-reported measure of neuropathy would aid in the management and assessment of oxaliplatininduced neuropathy in clinical practice and research. We sought to evaluate the content validity of the 13-item Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale(FACT/GOGNtx) for CRC patients receiving oxaliplatin.AIM To understand the neuropathy experiences of CRC patients and assess content validity of the FACT/GOG-Ntx.METHODS Semi-structured concept elicitation and cognitive debriefing interviews were conducted with 31 CRC patients experiencing peripheral neuropathy from current or previous oxaliplatin treatment. Interview data were analyzed using a constant comparative approach, and data were mapped to the FACT/GOG-Ntx to assess content validity.RESULTS Mean age of the sample was 54(range 34-82). The sample was primarily Caucasian(84%) and consisted of nearly equal numbers of men and women.Participants described 28 unique neuropathy symptoms; hand tingling(experienced by 87% of respondents); feet tingling(81%); hand numbness(68%);and feet numbness(84%) were most frequently mentioned. Neuropathy symptoms occurring on the feet were most often identified as most bothersome by participants. Eleven of the 13 FACT/GOG-Ntx items exhibited moderate to strong evidence of content validity. Two items related to trouble hearing and ringing in the ears had weak support; however, these items represent severe neuropathy and could be useful for a patient reported outcome measure.CONCLUSION The FACT/GOG-Ntx represents the key neuropathy experiences of CRC patients treated with oxaliplatin.
